SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 5.5 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS

被引：0
|
作者：
Genovese, M. C. [1 ]
Smolen, J. S. [2 ]
Takeuchi, T. [3 ]
Hyslop, D. [4 ]
Macias, W. L. [4 ]
Rooney, T. P. [4 ]
Chen, L. [4 ]
Dickson, C. L. [4 ]
Camp, J. R. [4 ]
Cardillo, T. E. [4 ]
Ishii, T. [5 ]
Winthrop, K. L. [6 ]
Garcia, E. G. [4 ]
机构：
[1] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[2] Med Univ Vienna, Vienna, Austria
[3] Keio Univ, Tokyo, Japan
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] Eli Lilly & Co, Kobe, Hyogo, Japan
[6] Oregon Hlth & Sci Univ, Portland, OR USA
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
375
引用
收藏
页码：S83 / S83
页数：1
相关论文
共 50 条
  • [31] Cardiovascular Safety - Update from up to 6 Years of Treatment with Baricitinib in Rheumatoid Arthritis Clinical Trials
    Weinblatt, Michael
    Taylor, Peter C.
    Burmester, Gerd R.
    Saifan, Chadi
    Walls, Chad D.
    Issa, Maher
    Rooney, Terence P.
    Takeuchi, Tsutomu
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [32] Cardiovascular Safety - Update from up to 6 Years of Treatment with Baricitinib in Rheumatoid Arthritis Clinical Trials
    Keystone, Edward
    Weinblatt, Michael
    Taylor, Peter
    Burmester, Gerd
    Saifan, Chadi
    Walls, Chad
    Issa, Maher
    Rooney, Terence
    Takeuchi, Tsutomu
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 805 - 805
  • [33] Cardiovascular Safety during Treatment with Baricitinib in Rheumatoid Arthritis
    Weinblatt, Michael
    Taylor, Peter C.
    Burmester, Gerd R.
    Witt, Sarah
    Saifan, Chadi
    Walls, Chad
    Rooney, Terence P.
    Chen, Lei
    Takeuchi, Tsutomu
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [34] Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
    Taylor, Peter C.
    Weinblatt, Michael E.
    Burmester, Gerd R.
    Rooney, Terence P.
    Witt, Sarah
    Walls, Chad D.
    Issa, Maher
    Salinas, Claudia A.
    Saifan, Chadi
    Zhang, Xin
    Cardoso, Anabela
    Gonzalez-Gay, Miguel A.
    Takeuchi, Tsutomu
    ARTHRITIS & RHEUMATOLOGY, 2019, 71 (07) : 1042 - 1055
  • [35] Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials
    Bieber, Thomas
    Katoh, Norito
    Simpson, Eric L.
    de Bruin-Weller, Marjolein
    Thaci, Diamant
    Torrelo, Antonio
    Sontag, Angelina
    Grond, Susanne
    Issa, Maher
    Lu, Xiaoyu
    Cardillo, Tracy
    Holzwarth, Katrin
    Thyssen, Jacob P.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
  • [36] Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials
    Harigai, Masayoshi
    Takeuchi, Tsutomu
    Smolen, Josef S.
    Winthrop, Kevin L.
    Nishikawa, Atsushi
    Rooney, Terence P.
    Saifan, Chadi G.
    Issa, Maher
    Isaka, Yoshitaka
    Akashi, Naotsugu
    Ishii, Taeko
    Tanaka, Yoshiya
    MODERN RHEUMATOLOGY, 2020, 30 (01) : 36 - 43
  • [37] The safety of baricitinib in patients with rheumatoid arthritis
    Honda, Suguru
    Harigai, Masayoshi
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (05) : 545 - 551
  • [38] Safety Profile of Upadacitinib up to 3 Years of Exposure in Patients with Rheumatoid Arthritis
    Cohen, Stanley
    Van Vollenhoven, Ronald F.
    Curtis, Jeffrey
    Calabrese, Leonard
    Zerbini, Cristiano A. F.
    Tanaka, Yoshiya
    Bessette, Louis
    Schlacher, Casey
    Shaw, Tim
    Liu, John
    Enejosa, Jeffrey
    Song, Yanna
    Burmester, Gerd
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [39] SAFETY PROFILE OF UPADACITINIB UP TO 3 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Cohen, S. B.
    Van Vollenhoven, R.
    Curtis, J. R.
    Calabrese, L.
    Zerbini, C.
    Tanaka, Y.
    Bessette, L.
    Schlacher, C.
    Shaw, T.
    Liu, J.
    Enejosa, J. J.
    Song, Y.
    Burmester, G. R.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 315 - 316
  • [40] Safety Profile of Upadacitinib up to 6.5 Years of Exposure in Patients with Rheumatoid Arthritis
    Cohen, S. B.
    van Vollenhofen, R.
    Curtis, J. R.
    Calabrese, L.
    Zerbini, C. A. F.
    Bessette, L.
    Richez, C.
    Strenholt, S.
    Coombs, D.
    Khan, N.
    Gara, A.
    Burmester, G. R.
    SWISS MEDICAL WEEKLY, 2023, 153 : 25S - 25S
12345